Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 10/20 | 0.39 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.38 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.38 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17813505 | 0.76 | HSP90AA1 (0.31) | HSP90AA1 | |
| SCHEMBL17813511 | 0.76 | IDH1 (0.40) | HSP90AA1 | |
| SCHEMBL19508034 | 0.76 | FGFR4 (0.40) | HSP90AA1HSP90AB1 | |
| SCHEMBL17813508 | 0.75 | RECQL (0.42) | CYP11B2BMPR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL17813500 | 0.74 | GRM5 (0.40) | HSP90AA1HSP90AB1 | |
| SCHEMBL46315 | 0.74 | CYP11B2 (0.50) | CYP11B2BMPR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL19200104 | 0.71 | ALDH1A1 (0.37) | CYP11B2 | |
| SCHEMBL17813506 | 0.71 | CYP11B2 (0.36) | CYP11B2BMPR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL25462212 | 0.70 | STK4 (0.40) | — | |
| SCHEMBL7948276 | 0.70 | KDM4E (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023083297-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-19 | — | — | WO | disclosed |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-08-03 | — | — | US | disclosed |
| US-9663520-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | CYP11B2 3712/4885BMPR1B 3047/4885BMPR1A 3208/4885 |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | CYP11B2 3712/4885BMPR1B 3047/4885BMPR1A 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.